Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project
Edinburgh, Scotland, and Villigen, Switzerland, 13 August 2024 – Cumulus Oncology, Europe’s first oncology-focused biotech creation company, announces that, in partnership with its collaborator leadXpro (LXP), key milestones have been achieved in their protein structure driven GPR68 drug discovery project. As a result, Cumulus has licensed the small molecule compounds and associated IP created during […]